ISRCTN11899726 https://doi.org/10.1186/ISRCTN11899726

A study to evaluate how inavolisib is processed in the body of participants with moderate and highly reduced kidney function

Submission date
15/11/2023

Recruitment status
No longer recruiting

Registration date
17/11/2023

Overall study status
Completed

Last Edited
05/12/2023

Condition category
Urological and Genital Diseases

[_] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[_] Results
[_] Individual participant data
[_] Record updated in last year

Plain English summary of protocol

Background and study aims
This study is testing a drug called inavolisib (also known as GDC-0077/RO7113755), which is being developed to treat certain kinds of cancer. Inavolisib is an experimental drug, which means health authorities have not approved inavolisib for the treatment of cancer or any other disease. The purpose of this study is to find out how much inavolisib gets into the body, and how long it takes the body to get rid of it (this is called pharmacokinetics [PK]) when given to participants with normal kidney function compared to participants with impaired kidney function. The other purpose of this study is to evaluate the safety and tolerability of inavolisib.

Who can participate?
People who are 18 to 80 years of age (inclusive), with normal kidney function or moderate and severe kidney damage can participate in this study.

What does the study involve?
Participants will be part of this study for approximately 6 weeks including screening and follow-up. The study will be conducted in the following parts:

1. Screening: During the screening period, participants will undergo certain screening tests and /or procedures to check if they are eligible to take part in this study. Participants will have one clinic visit and the screening period will be for approximately 32 days.
2. Dosing/Clinic Stay: Participants will receive a single dose of inavolisib by mouth during this period. They will be admitted to the clinic one day (Day -1) before inavolisib is administered and they will have to stay in the clinic for 5 days. Participants will have routine check-ups and blood samples will be collected during the clinic stay. They will be discharged on Day 5.
3. Follow-up Period: There will be a safety follow-up phone call 7 days after the study drug administration to check the participants' well-being after the treatment is finished.

What are the possible benefits and risks of participating?
Participants will be administered inavolisib only for research purposes and it is not intended that the participants will receive any benefit from it. However, the information learned in this study

may help future patients suffering from certain kinds of cancers.
Participants may have side effects from inavolisib, or from procedures used in this study. These can be mild to severe and even life-threatening, and they can vary from person to person. Inavolisib has had limited testing in humans and there may be side effects that are not known at this time. The known and potential side effects associated with inavolisib are listed below:

Known side effects: Increased blood sugar levels (hyperglycemia), diarrhea, vomiting, nausea, constipation, rash, inflammation of the lining of the mouth or ulcers of the lip or mouth (mucosal inflammation/stomatitis).

Potential side effects: Eye disorder (eye pain or sensitivity to light, blurred vision, cataract); inflammation of the large bowel [colon] (colitis); possible harm to a developing unborn baby including birth defects and/or miscarriage; inflammation of the lungs that may cause difficulty breathing and can be life-threatening (pneumonitis); low levels of white blood cells that may lead to increased risk of infections (depressed immune function); low levels of cells that help the blood to clot (platelets), which may cause bleeding problems and bruising; in males, reduced fertility or sterility.

There may be a risk in exposing an unborn child to the study drug, and not all potential risks are known at this time. Women and men must take precautions to avoid exposing an unborn child or a breastfed baby to the study treatment. Participants who are pregnant, or breastfeeding cannot take part in this study.

Where is the study run from?
F. Hoffmann-La Roche Ltd (Switzerland)

When is the study starting and how long is it expected to run for?
July 2023 to October 2024

Who is funding the study?
F. Hoffmann-La Roche Ltd (Switzerland)

Who is the main contact?
global.trial_information@roche.com

Contact information

Type(s)
Public, Scientific, Principal investigator

Contact name
Dr Dhruvit Sutaria

Contact details
Building 1, Grenzacherstrasse 124
Basel
Switzerland
CH-4070
+41 616878333
global.trial_information@roche.com

Additional identifiers

Clinical Trials Information System (CTIS)
Nil Known

ClinicalTrials.gov (NCT)
Nil Known

Protocol serial number
GP44944

Study information

Scientific Title
A Phase 1, open-label, single-dose study to evaluate the effect of moderate or severe renal impairment on the pharmacokinetics of inavolisib

Study objectives
The main purpose of this study is to evaluate the effect of moderate or severe renal impairment on the pharmacokinetics (PK) of inavolisib compared with demographically matched participants with normal renal function, following a single oral dose of inavolisib.

Ethics approval required
Ethics approval required

Ethics approval(s)
approved 14/08/2023, Salus IRB (2111 W. Braker Lane, Suite 100, Texas, Austin, 78758, United States of America; +1 512-380-1244; salus@salusirb.com), ref: None provided

Study design
Phase 1 open-label multi-center single-dose non-randomized parallel-group study

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Healthy Volunteers; Renal impairment

Interventions
Participants with normal renal function, and moderate and severe renal impairment will receive a single dose of inavolisib, 6 milligrams (mg), orally on Day 1.

Intervention Type
Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)
Inavolisib

Primary outcome(s)
1. Area under the concentration-time curve (AUC) from hour 0 to the last measurable concentration (AUC0-t) of inavolisib, assessed using model-independent approach from the plasma samples collected at multiple time points from Day 1 to Day 5
2. AUC extrapolated to infinity (AUC0-∞) of inavolisib, assessed using model-independent approach from the plasma samples collected at multiple time points from Day 1 to Day 5
3. Maximum observed concentration (Cmax) of inavolisib, assessed using model-independent approach from the plasma samples collected at multiple time points from Day 1 to Day 5

Key secondary outcome(s))
1. Number of participants with adverse events (AEs), and severity of AEs assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 5.0 (NCI CTCAE v5.0) from screening up to follow-up (approximately 6 weeks)

Completion date
22/10/2024

Eligibility

Key inclusion criteria
1. Participants must have a body weight of at least 45 kilograms (kg), and a body mass index (BMI) within the range of 18 - 40 kilograms per square meter (kg/m2) (inclusive).
2. Negative hepatitis panel (hepatitis B virus core antibody, hepatitis B surface antigen, and hepatitis C virus antibody) and negative human immunodeficiency virus (HIV) antibody screens.

Additional inclusion criteria for participants with normal renal function:
1. Participants must be in reasonably good health for their age group.
2. Estimated glomerular filtration rate (eGFR) of 90 millilitres per minute (mL/min), as calculated using 2021 Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) creatinine equation at screening and confirmed at Day -1.
3. Matched to participants with renal impairment in sex, age (±10 years), and body weight (±15%).

Additional inclusion criteria for participants with moderate renal impairment:
1. Participants with moderate renal impairment must have eGFR 30-59 mL/min
2. Participants must have a stable renal function, defined as either:
2.1. If the time interval between Screening and Check-in (Day -1) is greater than 7 days, eGFR value on Day -1 is within 20% of eGFR value at Screening, or
2.2. If the time interval between Screening and Check-in (Day -1) is within 7 days, eGFR value on Day -1 is within 20% of eGFR value at Screening and there is no clinically significant change in eGFR over the past 3 months.
3. Stable medication regimen for at least 1 month prior to Check-in (Day -1)

Additional inclusion criteria for participants with severe renal impairment:
1. Participants with severe renal impairment must have eGFR <30 mL/min and not be on dialysis
2. Participants must have a stable renal function, defined as either:

2.1. If the time interval between Screening and Check-in (Day -1) is greater than 7 days, eGFR value on Day -1 is within 20% of eGFR value at Screening, or
2.2. If the time interval between Screening and Check-in (Day -1) is within 7 days, eGFR value on Day -1 is within 20% of eGFR value at Screening and there is no clinically significant change in eGFR over the past 3 months.
3. Stable medication regimen for at least 1 month prior to Check-in (Day -1).

Participant type(s)
Healthy volunteer, Patient

Healthy volunteers allowed
No

Age group
Mixed

Lower age limit
18 years

Upper age limit
80 years

Sex
All

Key exclusion criteria
1. History of Type 1 diabetes or Type 2 diabetes requiring ongoing systemic treatment with 2 or more agents
2. Significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, hematological, pulmonary, cardiovascular, gastrointestinal (GI), neurological, or psychiatric disorder
3. Clinically significant and active liver disease, e.g., hepatitis, cirrhosis, or confirmed liver enzyme elevations.
4. History of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs except that appendectomy and hernia repair will be allowed.
5. Malabsorption syndrome or other condition that would interfere with enteral absorption. This includes gastric bypass surgery; gastric band surgery is allowed.
6. History of active or latent tuberculosis (TB), regardless of treatment history, or positive QuantiFERON® TB Gold test.

Additional exclusion criteria for participants with normal renal function:
1. Significant history or clinical manifestation of renal injury or disease (as determined by the investigator).
2. Uncomplicated cholecystectomy more than 5 years prior to enrolment is allowed unless the participant was ≥ 40 years old at the time of procedure; any cholecystectomy within 5 years of enrolment is exclusionary.

Additional exclusion criteria for participants with moderate and severe renal impairment:
1. Participants who have a functioning renal transplant or who are active on the transplant waiting list.

2. Blood potassium concentration <3 millimoles per litre (mmol/L) or >6 mmol/L at Screening
3. Hemoglobin concentration <9 grams per deciliter (g/dL) at Screening.

Date of first enrolment
26/10/2023

Date of final enrolment
22/10/2024

Locations

Countries of recruitment
United States of America

Study participating centre
Clinical Pharmacology of Miami, LLC
550 West 84th St Miami
Miami, Florida
United States of America
33014-3616

Study participating centre
Advanced Pharma CR, LLC
2950 NW 83rd St. Miami
Miami, Florida
United States of America
33147

Study participating centre
Alliance for Multispecialty Research, LLC (AMR)
1928 Alcoa Highway, Suite 107, Knoxville,
Knoxville, Tennessee
United States of America
37920

Study participating centre
Omega Research Orlando, LLC
816 Mercy Drive
Orlando, Florida
United States of America
32808

Study participating centre
Orlando Clinical Research Center (OCRC-FL)
5055 S Orange Ave
Orlando, Florida
United States of America
32809

Study participating centre
Pinnacle Research Group
409 E 10th St Suite 200
Anniston, Alabama
United States of America
36207

Sponsor information

Organisation
F. Hoffmann-La Roche Ltd

Funder(s)

Funder type
Industry

Funder Name
F. Hoffmann-La Roche Ltd

Results and Publications

Individual participant data (IPD) sharing plan
The datasets generated during and/or analysed during the current study are not expected to be made available due to participant-level data not being a regulatory requirement.

IPD sharing plan summary
Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes

Study website	Study website	11/11/2025	11/11/2025	No	Yes